Creative Planning acquired a new stake in shares of Myovant Sciences Ltd (NYSE:MYOV) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 11,818 shares of the company’s stock, valued at approximately $183,000.
Several other large investors also recently made changes to their positions in the stock. Eventide Asset Management LLC boosted its stake in Myovant Sciences by 9.6% in the 3rd quarter. Eventide Asset Management LLC now owns 4,694,917 shares of the company’s stock worth $24,414,000 after purchasing an additional 409,305 shares during the period. Great Point Partners LLC bought a new position in Myovant Sciences in the 3rd quarter worth approximately $1,690,000. Vanguard Group Inc. bought a new position in Myovant Sciences in the 2nd quarter worth approximately $1,119,000. LVW Advisors LLC bought a new position in Myovant Sciences in the 3rd quarter worth approximately $598,000. Finally, Morgan Stanley boosted its stake in Myovant Sciences by 1,970.7% in the 2nd quarter. Morgan Stanley now owns 74,337 shares of the company’s stock worth $673,000 after purchasing an additional 70,747 shares during the period. Institutional investors own 39.44% of the company’s stock.
Several research analysts have weighed in on MYOV shares. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. ValuEngine downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Citigroup started coverage on Myovant Sciences in a research note on Sunday, February 2nd. They issued a “neutral” rating and a $15.00 price target for the company. Goldman Sachs Group restated a “buy” rating and issued a $20.00 price target (up from $18.00) on shares of Myovant Sciences in a research note on Tuesday, November 19th. Finally, JMP Securities restated a “buy” rating and issued a $34.00 price target on shares of Myovant Sciences in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Myovant Sciences has an average rating of “Buy” and an average price target of $21.54.
In other news, insider Kim Sablich sold 2,585 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $16.22, for a total transaction of $41,928.70. Following the sale, the insider now directly owns 64,530 shares of the company’s stock, valued at approximately $1,046,676.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Frank Karbe sold 19,701 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $15.55, for a total value of $306,350.55. Following the sale, the insider now directly owns 43,324 shares in the company, valued at $673,688.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 4,046,099 shares of company stock worth $61,228,506 and have sold 46,144 shares worth $711,963. 3.68% of the stock is owned by corporate insiders.
Shares of MYOV opened at $11.71 on Friday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -3.16 and a beta of 2.11. Myovant Sciences Ltd has a 1 year low of $4.14 and a 1 year high of $26.02. The business’s 50 day simple moving average is $13.77 and its 200-day simple moving average is $9.93. The company has a debt-to-equity ratio of 5.88, a current ratio of 2.79 and a quick ratio of 2.79.
Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.16). On average, sell-side analysts expect that Myovant Sciences Ltd will post -3.29 earnings per share for the current year.
Myovant Sciences Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Further Reading: Using other technical indicators with support levels
Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd (NYSE:MYOV).
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.